42 completed, 18 unknown, 15 recruiting, 11 active not recruiting. 109 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 109 | Completed 42, Unknown 18, Recruiting 15, Active not recruiting 11, Terminated 9, Withdrawn 7, Not yet recruiting 6, Enrolling by invitation 1 |
Follow Prostatic Neoplasms: new trials by email Literature Review of Prostatic Neoplasms trials Research Report on Prostatic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery Drug: 68-Ga PSMA11, Adaptive stereotactic ablative radiotherapy (SABR), 68Ga-PSMA-11 - Prostate Cancer, Castration Sensitive Prostate Cancer | Early Phase 1 | Not yet recruiting | University of Texas Southwestern Medical Center | 30 | 2026-10-01 | 2026-08-24 |
| PSMA-Targeting Dual-Target Radiopharmaceuticals for Prostate Cancer Imaging 68Ga-Labeled EphA2/PSMA Dual-Target Radiotracer PET/CT imaging, 68Ga-Labeled ACP3/PSMA Dual-Target Radiotracer PET/CT imaging - Prostate Cancer | Early Phase 1 | Active not recruiting | The First Affiliated Hospital of Soochow University | 30 | 2026-09-24 | 2026-11-12 |
| Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer [64Cu]CM500, [68Ga]CM500, PET/MR - Bladder Cancer, Glioma | Early Phase 1 | Not yet recruiting | Lumina Pharmaceuticals Inc | 40 | 2026-09-01 | 2026-08-28 |
| The Safety, Dosimetry and Efficacy of 177Lu-FC516 in Patients With Prostate Cancer 177Lu-FC516 - Prostate Cancer | Early Phase 1 | Recruiting | FindCure Biosciences (ZhongShan) Co., Ltd. | 13 | 2026-08-31 | 2026-09-04 |
| Preoperative Semaglutide Prior to Radical Prostatectomy Semaglutide 2.4 mg - Prostate Cancer | Early Phase 1 | Not yet recruiting | Banner Health | 20 | 2026-07-01 | 2026-07-27 |
| First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer [177Lu]Lu-DOTA-STR-17126, [68Ga]Ga-DOTA-STR-17126 - Metastatic Breast Cancer, Metastatic Prostate Cancer | Early Phase 1 | Recruiting | Integrated Haematology and Oncology Network | 20 | 2026-05-28 | 2026-06-10 |
| RET-Targeted Molecular Imaging Probes in Prostate Cancer RET-targeted PET/CT molecular imaging, PSMA-targeted PET/CT imaging - Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Prostate Cancer | Early Phase 1 | Active not recruiting | Xiangya Hospital of Central South University | 50 | 2026-04-03 | 2026-10-21 |
| Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical Study Docetaxel+ Darolutamide + Homoharringtonine+ Androgen Deprivation Therapy - Prostate Cancer | Early Phase 1 | Not yet recruiting | Zhongda Hospital | 94 | 2026-04-01 | 2026-04-08 |
| The Dosimetry, Safety and Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer ⁶⁸Ga-FC516, ⁶⁸Ga-FC516 and ⁶⁸Ga-labeled prostate cancer-targeting tracer - Healthy Adult, Prostate Cancer | Early Phase 1 | Recruiting | FindCure Biosciences (ZhongShan) Co., Ltd. | 10 | 2026-03-09 | 2026-09-09 |
| Safety, Tolerability and Preliminary Efficacy of 161Tb-LNC1011 (PSMA Radioligand) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) 161Tb-LNC1011 - Prostate Cancer | Early Phase 1 | Not yet recruiting | Peking Union Medical College Hospital | 15 | 2026-01-01 | 2026-02-02 |
| Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial Biopsy of Prostate, Biospecimen Collection, Computed Tomography - Prostate Carcinoma | Early Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 30 | 2025-11-14 | 2026-03-10 |
| Akkermansia Muciniphilia and Metabolic Side Effects of ADT Apple Cider Vinegar - Prostate Cancer, Metabolic Syndrome | Early Phase 1 | Recruiting | Western University | 30 | 2025-07-02 | 2025-08-20 |
| Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study Tirzepatide - Diabetes, Prostate Cancer | Early Phase 1 | Recruiting | M.D. Anderson Cancer Center | 30 | 2025-07-02 | 2026-09-25 |
| 18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot Study 18F-rhPSMA-7.3 - Prostate Cancer | Early Phase 1 | Withdrawn | University of Alabama at Birmingham | 2025-04-30 | 2024-09-25 | |
| Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer anti-IGF-1R mAb (Teprotumumab/IBI311) + anti-PD-1 mAb (Tislelizumab) - mCRPC | Early Phase 1 | Active not recruiting | Shanghai Changzheng Hospital | 7 | 2025-03-10 | 2026-07-23 |
| Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in PCa Diagnosis, Recurrence, and Metastasis [18F]AlF-PSMA-N5, [18F]F-DCFPyL - Prostate Cancer, PET/CT | Early Phase 1 | Recruiting | Anhui Provincial Hospital | 30 | 2024-12-19 | 2025-01-03 |
| A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer lutetium (177Lu) rhPSMA 10.1 and Pluvicto® - Metastatic Prostate Cancer | Early Phase 1 | Terminated | Blue Earth Therapeutics Ltd | 17 | 2024-10-31 | 2025-09-25 |
| 68Ga-NTA-476 Imaging in Prostate Cancer 68Ga-NTA-476 - Prostate Cancer | Early Phase 1 | Completed | Melbourne Theranostic Innovation Centre | 10 | 2024-09-13 | 2025-09-25 |
| 68Ga-AAZTA-NI-093 PET/CT: First-in-human Study 68Ga-AAZTA-NI-093 - Prostate Cancer (Adenocarcinoma) | Early Phase 1 | Unknown | First Affiliated Hospital of Fujian Medical University | 10 | 2024-09-01 | 2024-09-25 |
| [68Ga]Ga-P17-079 in the Diagnosis and Treatment of Metastatic Prostate Cancer P17-079, P16-093, or P15-041 PET/CT - Metastatic Prostate Cancer (mPC) | Early Phase 1 | Enrolling by invitation | Peking Union Medical College Hospital | 40 | 2024-09-01 | 2025-03-07 |
Showing 20 of 109. Sign in to see all of them.
Breast Neoplasms (11) · Neoplasm Metastasis (6) · Neoplasms (6) · Ovarian Neoplasms (4) · Pancreatic Neoplasms (4) · Urinary Bladder Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Colonic Neoplasms (3) · Colorectal Neoplasms (3) · Lung Neoplasms (3) · Uterine Cervical Neoplasms (3) · Brain Neoplasms (2) · Carcinoma, Renal Cell (2) · Diabetes Mellitus (2)
Genital Diseases (109) · Genital Diseases, Male (109) · Genital Neoplasms, Male (109) · Male Urogenital Diseases (109) · Neoplasms by Site (109) · Prostatic Diseases (109) · Urogenital Diseases (109) · Urogenital Neoplasms (108) · Neoplasms (103) · Breast Diseases (11) · Skin Diseases (11) · Skin and Connective Tissue Diseases (11) · Pathological Conditions, Signs and Symptoms (10) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9)
Magnetic Resonance Spectroscopy (9) · gallium 68 PSMA-11 (8) · 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (4) · Specimen Handling (4) · Positron Emission Tomography Computed Tomography (3) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (2) · 68Ga-DKFZ-PSMA-11 (2) · Abiraterone Acetate (2) · HhAntag691 (2) · Radiation (2) · Standard of Care (2) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (2) · bicalutamide (2) · enzalutamide (2) · 130-nm albumin-bound paclitaxel (1)
Jonsson Comprehensive Cancer Center (6) · Mayo Clinic (6) · Peking Union Medical College Hospital (5) · Anhui Provincial Hospital (4) · National Cancer Institute (NCI) (4) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · First Affiliated Hospital of Fujian Medical University (3) · M.D. Anderson Cancer Center (3) · University of Wisconsin, Madison (3) · Affiliated Hospital of Jiangnan University (2) · FindCure Biosciences (ZhongShan) Co., Ltd. (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Johns Hopkins University (2) · Northwestern University (2) · University of Colorado, Denver (2)
United States (69) · China (22) · Australia (3) · Canada (3) · United Kingdom (3) · Netherlands (2) · Denmark (1) · Georgia (1) · Jamaica (1) · Pakistan (1) · Spain (1)
Chunjing Yu (3) · Qiang Xie (3) · Jingsong Zhang, M.D., Ph.D. (2) · Misop Han, M.D., M.S. (2) · Rahul Aggarwal, MD (2) · Adriana Coletta (1) · Allan Pantuck, M.D. (1) · Ashley E Ross (1) · Benjamin Franc, MD (1) · Celina Shirazipour, PhD (1) · Christos Kyriakopoulos, MD (1) · Dan Pryma, MD (1) · Daniel Song, M.D. (1)
PMID 21233180, PMID 27826729, PMID 28806263, PMID 28894899, PMID 29180633, PMID 29602821, PMID 32466781, PMID 33568190, PMID 36358643, PMID 37914976, PMID 38104131, PMID 38782459, PMID 39136560, PMID 39254446, PMID 39928105, PMID 40177325, PMID 41698328, PMID 41759531, PMID 41833067
P30CA015083 (2), N01CM37120 (1), P30CA006516 (1), P30CA006973 (1), P30CA042014 (1), P30CA060553 (1), P30CA072720 (1), R01CA151395 (1), R01CA211150 (1), R01CA214554 (1), R01CA218547 (1), R01CA238379 (1), R01CA300053 (1), R01EB017449 (1), R44CA275590 (1)